Michele Ghielmini

Michele Ghielmini

UNVERIFIED PROFILE

Are you Michele Ghielmini?   Register this Author

Register author
Michele Ghielmini

Michele Ghielmini

Publications by authors named "Michele Ghielmini"

Are you Michele Ghielmini?   Register this Author

59Publications

1824Reads

47Profile Views

Risk factors for renal toxicity after inpatient cisplatin administration.

BMC Pharmacol Toxicol 2020 Mar 2;21(1):19. Epub 2020 Mar 2.

Istituto Oncologico della Svizzera Italiana (IOSI), Oncology Clinic, Via Ospedale 12, 6500, Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40360-020-0398-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052961PMC
March 2020

Diagnostic Performance of F-FDG PET or PET/CT for Detection of Post-Transplant Lymphoproliferative Disorder: A Systematic Review and a Bivariate Meta-Analysis.

Diagnostics (Basel) 2020 Feb 12;10(2). Epub 2020 Feb 12.

Academic Education Research and Innovation Area, General Directorate, Ente Ospedaliero Cantonale, CH-6500 Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/diagnostics10020101DOI Listing
February 2020

Primary Cutaneous Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma.

Am J Dermatopathol 2019 Aug;41(8):602-605

Oncologia Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000001348DOI Listing
August 2019

Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial.

Oral Oncol 2018 07 28;82:144-151. Epub 2018 May 28.

Fondazione IRCCS Istituto Nazionale dei Tumori, Integrated Biology Platform, Department of Applied Research and Technology Development, Via Amadeo 42, I-20133 Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2018.05.013DOI Listing
July 2018

Choosing wisely in oncology: necessity and obstacles.

ESMO Open 2018 11;3(5):e000382. Epub 2018 Jul 11.

Medical Oncology Clinic, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2018-000382DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045771PMC
July 2018

Pros and cons of rituximab maintenance in follicular lymphoma.

Cancer Treat Rev 2017 Jul 16;58:34-40. Epub 2017 Jun 16.

Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.05.007DOI Listing
July 2017

Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.

J Clin Oncol 2017 Feb 28;35(5):552-560. Epub 2016 Dec 28.

Qian Shi and Daniel J. Sargent, Mayo Clinic, Rochester; Bruce A. Peterson, University of Minnesota, Minneapolis, MN; Christopher R. Flowers, Winship Cancer Institute of Emory University, Atlanta, GA; Wolfgang Hiddemann and Eva Hoster, Ludwig-Maximilians University Hospital, Munich; Michael Herold, HELIOS Kliniken, Erfurt, Germany; Robert Marcus, Addenbrooke's Hospital, Cambridge, United Kingdom; Anton Hagenbeek, Academic Medical Center, Amsterdam, the Netherlands; Eva Kimby, Karolinska Institutet, Stockholm, Sweden; Howard Hochster, Yale Cancer Center, New Haven, CT; Umberto Vitolo, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin; Marco Ladetto, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy; Emmanuel Gyan, University Hospital, Tours; Franck Morschhauser, Service Université de Lille 2, Lille; Gilles Salles, Université Claude Bernard, Pierre Bénite, France; Michele Ghielmini and Emanuele Zucca, Oncology Institute of Southern Switzerland, Bellinzona; Michele Ghielmini and Emanuele Zucca, Swiss Group for Clinical Cancer Research, Bern; Tina Nielsen, F. Hoffmann-La Roche, Basel; Sabine De Bedout, Celgene, Boudry, Switzerland; Tommy Fu, Celgene, Summit, NJ; Nancy Valente, Genentech, South San Francisco, CA; and Nathan H. Fowler, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.8651DOI Listing
February 2017

Rituximab: 13 open questions after 20years of clinical use.

Cancer Treat Rev 2017 Feb 22;53:38-46. Epub 2016 Dec 22.

Oncology Institute of Southern Switzerland, Ospedale San Giovanni, 6500 Bellinzona, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2016.11.015DOI Listing
February 2017

Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?

Leuk Lymphoma 2017 01 4;58(1):30-36. Epub 2016 Nov 4.

a Department of Medical Oncology , Oncology Institute of Southern Switzerland , Bellinzona , Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2016.1248963DOI Listing
January 2017

Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How.

Mediterr J Hematol Infect Dis 2016 7;8(1):e2016062. Epub 2016 Nov 7.

Istituto Oncologico della Svizzera Italiana, Ospedale San Giovanni 6500 Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4084/MJHID.2016.062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111519PMC
November 2016

Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options.

Expert Rev Anticancer Ther 2015 28;15(11):1337-49. Epub 2015 Sep 28.

b 2 Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.2015.1092386DOI Listing
June 2016

Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.

J Clin Oncol 2016 Feb 28;34(5):495-500. Epub 2015 Dec 28.

Christian Taverna, Kantonsspital Münsterlingen, Münsterlingen; Felicitas Hitz, Kantonsspital St Gallen, St Gallen; Walter Mingrone, Kantonsspital Aarau/Olten, Olten; Thomas Pabst, Inselspital Bern; Christine Biaggi Rudolf, Stéphanie Rondeau, and Corinne Rusterholz, Swiss Group for Clinical Cancer Research SAKK, Bern; Daniel Rauch, Spital Thun Simmental, Thun; Andreas Lohri, Kantonsspital Liestal, Liestal; Ingmar A.F.M. Heijnen, University Hospital Basel, Basel; Emanuele Zucca and Michele Ghielmini, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Giovanni Martinelli, Anna Vanazzi, and Daniele Laszlo, Istituto Europeo di Oncologia, Milan, Italy; Lidija Cevreska, University Clinic for Hematology, Skopje, Macedonia; Auro del Giglio, ABC Fondation School of Medicine, Sao Paulo, Brazil; Johann Raats, Panorama Oncology Unit, Cape Town; and Daniel A. Vorobiof, Sandton Oncology Center, Johannesburg, South Africa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.3968DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872010PMC
February 2016

Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98).

Br J Haematol 2015 Jan 21;168(1):145-8. Epub 2014 Aug 21.

Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton, Southampton, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13071DOI Listing
January 2015

Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management.

Oncologist 2013 30;18(8):954-64. Epub 2013 Jul 30.

Department of Hematology, Oncology, and Palliative Care, Schwarzwald-Baar Clinic, Academic Teaching Hospital, University of Freiburg, Villingen-Schwenningen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2013-0079DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755934PMC
May 2014

Open questions in the management of mantle cell lymphoma.

Cancer Treat Rev 2013 Oct 13;39(6):602-9. Epub 2013 Feb 13.

Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2012.12.013DOI Listing
October 2013

Risk factors of central nervous system relapse in mantle cell lymphoma.

Leuk Lymphoma 2013 Sep 20;54(9):1908-14. Epub 2013 Feb 20.

Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont and Azienda Ospedaliera Universitaria Maggiore della Carità, Novara, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2013.767454DOI Listing
September 2013

Managing newly diagnosed follicular lymphoma: state of the art and future perspectives.

Expert Rev Anticancer Ther 2013 Mar;13(3):313-25

State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer Center, Guangzhou, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.13.6DOI Listing
March 2013

Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.

J Natl Cancer Inst 2011 Dec 21;103(23):1799-806. Epub 2011 Oct 21.

Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah-Tikva 49100, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djr418DOI Listing
December 2011

Multimodality therapies and optimal schedule of antibodies: rituximab in lymphoma as an example.

Hematology Am Soc Hematol Educ Program 2005 :321-8

Oncology Inst. of Southern Switzerland, Ospedale San Giovanni, Bellinzona 6500, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2005.1.321DOI Listing
November 2009

Prognosis of acute myeloid leukemia in the general population: data from southern Switzerland.

Tumori 2009 May-Jun;95(3):303-10

Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
September 2009

Response to oxaliplatin with cetuximab in minor salivary gland adenoid cystic carcinoma.

Tumori 2009 May-Jun;95(3):378-81

Division of Medical Oncology Oncology, Institute of Southern Switzerland, Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
September 2009

How I treat mantle cell lymphoma.

Blood 2009 Aug 25;114(8):1469-76. Epub 2009 Jun 25.

Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2009-02-179739DOI Listing
August 2009

Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas.

Oncologist 2009 May 1;14(5):511-25. Epub 2009 May 1.

Oncology Institute of Southern Switzerland, Ospedale S. Giovanni, 6500 Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2008-0214DOI Listing
May 2009

First-line treatment of follicular lymphoma: a patient-oriented algorithm.

Leuk Lymphoma 2009 Mar;50(3):325-34

Department of Medical Oncology, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1080/1042819080271351
Publisher Site
http://dx.doi.org/10.1080/10428190802713513DOI Listing
March 2009

Peliosis hepatis in cancer patients mimicking infection and metastases.

Onkologie 2009 Feb 20;32(1-2):54-6. Epub 2009 Jan 20.

Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/184579
Publisher Site
http://dx.doi.org/10.1159/000184579DOI Listing
February 2009

Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.

J Natl Cancer Inst 2009 Feb 10;101(4):248-55. Epub 2009 Feb 10.

Institute of Hematology, Beilinson Hospital, Rabin Medical Center, Petah-Tikva, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djn478DOI Listing
February 2009

Monoclonal antibodies for the treatment of hematologic malignancies: schedule and maintenance therapy.

Semin Hematol 2008 Apr;45(2):75-84

Oncology Institute of Southern Switzerland (IOSI), Ospedale San Giovanni, Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2008.02.006DOI Listing
April 2008

Adjuvant chemotherapy (ECF regimen) for patients with gastric adenocarcinoma.

Hepatogastroenterology 2007 Apr-May;54(75):969-72

Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
August 2007

Patient benefits of maintenance immunotherapy.

Leuk Res 2006 Mar;30 Suppl 1:S22-6

Oncology Institute of Souther Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0145-2126(06)80005-6DOI Listing
March 2006

Adding rituximab to cyclophosphamide, vincristine and prednisone increases time to treatment failure or progression in people with untreated stage III/IV follicular lymphoma.

Cancer Treat Rev 2005 Dec 10;31(8):644-7. Epub 2005 Nov 10.

Oncology Institute of Southern Switzerland, Ospedale San Giovanni, 6500 Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2005.09.010DOI Listing
December 2005

Does the FLIPI apply to grade 3 follicular lymphoma?

Blood 2005 Jun;105(12):4892; author reply 4892-3

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2005-01-0053DOI Listing
June 2005

Treatment of malignant lymphoma.

Swiss Med Wkly 2004 Aug;134(33-34):472-80

Oncology Institute of Southern Switzerland, Ospedale Civico, CH-6900 Lugano.

View Article

Download full-text PDF

Source
http://dx.doi.org/2004/33/smw-10341DOI Listing
August 2004

Overview of antibody therapy in B-cell non-Hodgkin's lymphoma.

Clin Lymphoma 2003 Aug;4 Suppl 1:S5-12

Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/clm.2003.s.002DOI Listing
August 2003

Rituximab therapy for indolent non-Hodgkin's lymphoma.

Anticancer Drugs 2002 Nov;13 Suppl 2:S11-7

University Medical Center Utrecht, Department of Hematology, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
November 2002

Mantle cell lymphoma: new treatments targeted to the biology.

Clin Lymphoma 2002 Sep;3(2):90-6

Department of Experimental Hematology, Bart and The London Queen Mary's School of Medicine and Dentistry, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/clm.2002.n.014DOI Listing
September 2002